Pol S., et al. - Patients with chronic hepatitis B virus (HBV) infection have a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]), and nucleos(t)ide analogues (NUCs) are linked with a reduction in these complications, so researchers examined how NUCS tenofovir and entecavir influence these complications in patients treated for HBV infection. They included 1,800 patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort; of these patients, 986 received tenofovir and 814 received entecavir. In this large prospective cohort of predominantly non‐cirrhotic French patients, tenofovir‐ and entecavir‐treated patients exhibited no differences in the risk of liver‐related events or death.